References - Homocysteine in Protein Structure/Function and Human Disease - page 144

262. Wehr H, Bednarska-Makaruk M, Graban A, Lipczynska-Lojkowska W, Rodo M, Bochynska
A, et al. Paraoxonase activity and dementia. J Neurol Sci. 2009;283(1-2):107-8.
263. Harel M, Aharoni A, Gaidukov L, Brumshtein B, Khersonsky O, Meged R, et al. Structure
and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic
enzymes. Nat Struct Mol Biol. 2004;11(5):412-9.
264. Ben-David M, Elias M, Filippi JJ, Dunach E, Silman I, Sussman JL, et al. Catalytic versatility
and backups in enzyme active sites: the case of serum paraoxonase 1. J Mol Biol. 2012;418
(3-4):181-96.
265. Jarvik GP, Hatsukami TS, Carlson C, Richter RJ, Jampsa R, Brophy VH, et al. Paraoxonase
activity, but not haplotype utilizing the linkage disequilibrium structure, predicts vascular
disease. Arterioscler Thromb Vasc Biol. 2003;23(8):1465-71.
266. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD, et al.
Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192)
or PON1(55) genotype. Arterioscler Thromb Vasc Biol. 2000;20(11):2441-7.
267. Bayrak A, Bayrak T, Demirpence E, Kilinc K. Differential hydrolysis of homocysteine
thiolactone by purified human serum (192)Q and (192)R PON1 isoenzymes. J Chromatogr
B Analyt Technol Biomed Life Sci. 2011;879(1):49-55.
268. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, et al. Paraoxonase status in
coronary heart disease: are activity and concentration more important than genotype?

Arterioscler Thromb Vasc Biol. 2001;21(9):1451-7.
269. Domagała TB, Łacinski M, Trzeciak WH, Mackness B, Mackness MI, Jakubowski H. The
correlation of homocysteine-thiolactonase activity of the paraoxonase (PON1) protein with
coronary heart disease status. Cell Mol Biol (Noisy-le-Grand). 2006;52(5):4-10.
270. Robert K, Chasse JF, Santiard-Baron D, Vayssettes C, Chabli A, Aupetit J, et al. Altered gene
expression in liver from a murine model of hyperhomocysteinemia. J Biol Chem. 2003;278
(34):31504-11.
271. Lazo JS, Humphreys CJ. Lack of metabolism as the biochemical basis of bleomycin-induced
pulmonary toxicity. Proc Natl Acad Sci USA. 1983;80(10):3064-8.
272. Schwartz DR, Homanics GE, Hoyt DG, Klein E, Abernethy J, Lazo JS. The neutral cysteine
protease bleomycin hydrolase is essential for epidermal integrity and bleomycin resistance.
Proc Natl Acad Sci USA. 1999;96(8):4680-5.
273. Takeda A, Higuchi D, Yamamoto T, Nakamura Y, Masuda Y, Hirabayashi T, et al. Purifica-
tion and characterization of bleomycin hydrolase, which represents a new family of cysteine
proteases, from rat skin. J Biochem (Tokyo). 1996;119(1):29-36.
274. Kamata Y, Itoh Y, Kajiya A, Karasawa S, Sakatani C, Takekoshi S, et al. Quantification of
neutral cysteine protease bleomycin hydrolase and its localization in rat tissues. J Biochem
(Tokyo). 2007;141(1):69-76.
275. Nishimura C, Tanaka N, Suzuki H, Tanaka N. Purification of bleomycin hydrolase with a
monoclonal antibody and its characterization. Biochemistry. 1987;26(6):1574-8.
276. Sebti SM, Mignano JE, Jani JP, Srimatkandada S, Lazo JS. Bleomycin hydrolase: molecular
cloning, sequencing, and biochemical studies reveal membership in the cysteine proteinase
family. Biochemistry. 1989;28(16):6544-8.
277. Bromme D, Rossi AB, Smeekens SP, Anderson DC, Payan DG. Human bleomycin hydro-
lase: molecular cloning, sequencing, functional expression, and enzymatic characterization.
Biochemistry. 1996;35(21):6706-14.
278. Zheng W, Johnston SA, Joshua-Tor L. The unusual active site of Gal6/bleomycin hydrolase
can act as a carboxypeptidase, aminopeptidase, and peptide ligase. Cell. 1998;93(1):103-9.
279. Niemer I, Muller G, Strobel G, Bandlow W. Bleomycin hydrolase (Blh1p), a multi-sited thiol
protease in search of a distinct physiological role. Curr Genet. 1997;32(1):41-51.
280. Okamura Y, Nomoto S, Hayashi M, Hishida M, Nishikawa Y, Yamada S, et al. Identification
of the bleomycin hydrolase gene as a methylated tumor suppressor gene in hepatocellular
carcinoma using a novel triple-combination array method. Cancer Lett. 2011;312(2):150-7.